Discovery of Non-Carboxylic Steroidal FXR Agonist as a Promising Preclinical Candidate for Metabolic Dysfunction-Associated Steatohepatitis
achieves its promising efficacy and safety profile by the dual-path strategy that enhances FXR/TGR5 activity while suppressing MRGPRX4, supporting its further development as a novel therapeutic agent for MASH.
Authors
- S Li
- Zhenzhu Sun
- Chuyu Dong
- J J Li
- Wenjing Li (ORCID: https://orcid.org/0000-0002-8931-5433)
- Yi Lin
- Xiaoxiao Liu (ORCID: https://orcid.org/0009-0007-2086-3005)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-0837-730X)
- Bing Gu (ORCID: https://orcid.org/0000-0001-7764-3213)
- Zhe Zhang
- Xiaomin Zheng
- Pengru Li
Institutions
- Intelligent Synthetic Biology Center (KR)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-05-08
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03220
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhongshan Science and Technology Bureau